Palatin Technologies, Inc.

Palatin Technologies, Inc.

Palatin Technologies, Inc. company was founded in 1986 and is based in Cranbury, New Jersey. Palatin Technologies, Inc., a biopharmaceutical company, engages in the discovery and development of peptide, peptide mimetic, and small molecule agonist compounds with a focus on melanocortin (MC) and natriuretic peptide receptor systems in the United States. The company's products under development include PL-3994, a peptide mimetic natriuretic peptide receptor A agonist for the treatment of heart failure; Bremelanotide, a peptide melanocortin receptor agonist for the treatment of sexual dysfunction, targeting female sexual dysfunction and erectile dysfunction in patients non-responsive to current therapies; and PL-6983, a peptide melanocortin receptor agonist for the treatment of female sexual dysfunction. Its products in development also comprise melanocortin receptor-based compounds for treatment of obesity, diabetes, and related metabolic syndrome; and NeutroSpec, a radiolabeled monoclonal antibody product for imaging and diagnosing infection. Palatin Technologies, Inc. has a licensing and research collaboration agreement with AstraZeneca AB to discover, develop, and commercialize compounds that target melanocortin receptors for the treatment of obesity, diabetes, and related metabolic syndrome.

Contact Details

Office Address

Palatin Technologies, Inc.
4-C Cedar Brook Drive, Cedar Brook Corporate Center
Cranbury, NJ, USA 08512
Phone: (609) 495-2200
Fax: (609) 495-2201

Executives

Co-Founder and Chairman

Dr. John K. A. Prendergast

Co-founder & Chief Exec. Officer

Dr. Carl Spana

Business Reviews for Palatin Technologies, Inc.

Related Companies